Browse studies

Find your next paid study

27,355 recruiting studies available now

Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia (The ALIGN-AML Trial)

This is a phase 2 randomized controlled trial to evaluate whether a geriatric assessment (GA)-guided treatment strategy reduces treatment-related toxicity and …

Acute Myeloid Leukemia

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of RochesterNCT07735208

Phase 1

REPEAT: RE-irradiation With a Partial brEast, Accelerated Technique: A Single-Center, Multi-site, Prospective, Phase I/II Clinical Trial

This study is to determine whether acute treatment-associated adverse events following breast re-irradiation with aPBI are acceptably low and to assess local c…

Breast Cancer Recurrent

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Dartmouth-Hitchcock Medical CenterNCT07612254

Phase 1

A Phase I/II Study Evaluating the Safety and the Efficacy of SMART101 Injection to Accelerate Immune Reconstitution After T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Adult Patients With Hematological Malignancies

The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitu…

Hematological Malignancies

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Smart Immune SASNCT04959903

Alpha-1 Antitrypsin PiMZ Longitudinal Cohort (PiMZ Logic)

Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous populatio…

Alpha 1-Antitrypsin DeficiencyEmphysema or COPD

Estimated

~$10 – $750

Actual pay is set by the research site.

Columbia UniversityNCT06505603

A Multi-Modal Wearable Sensor for Early Detection of Cognitive Decline and Remote Monitoring of Cognitive-Motor Decline Over Time

This observational study will enroll approximately 100 participants evenly split by cognitive status (Cognitively Impaired vs Non-Cognitively Impaired), and in…

Mild Cognitive Impairment (MCI)Older Adults With Cognitive DeclineOlder Adults

Estimated

~$10 – $1,125

Actual pay is set by the research site.

BioSensicsNCT07780162

Phase 3

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or g…

GanglioneuroblastomaGanglioneuroblastoma, NodularNeuroblastoma

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Children's Oncology GroupNCT03126916

Edwards PASCAL Transcatheter Tricuspid Valve Repair System Coverage With Evidence Development Study (The CLASP III TR CED Study)

This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who rec…

Tricuspid RegurgitationHeart Valve DiseasesHeart Diseases+2 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Edwards LifesciencesNCT07859709

Phase 2

A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung can…

Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$75 – $3,000

Actual pay is set by the research site.

SWOG Cancer Research NetworkNCT06031688

Phase 2

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Pharmacodynamics, and Preliminary Efficacy of S-606001 as an Add-on to Enzyme Replacement Therapy in Patients With Late-onset Pompe Disease

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an…

Pompe Disease

Estimated

~$75 – $3,000

Actual pay is set by the research site.

ShionogiNCT07123155

Phase 2

From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects

This is a multicenter prospective study of patients who currently have stably implanted spinal cord simulators. Patients will be randomly assigned to turn on o…

Chronic Pain

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Massachusetts General HospitalNCT05661903

Phase 1

A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with rela…

B-cell Non-Hodgkins Lymphoma (B-NHL)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT05685173

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

Estimated

~$150 – $4,500